The Market Reports

Synopsis
The global market for LFA-based Cardiac Marker was estimated to be worth US$ 3839 million in 2024 and is forecast to a readjusted size of US$ 5853 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
LFA-based Cardiac Marker is a cardiac marker test based on lateral flow chromatography technology. Lateral flow chromatography technology is a detection method based on the principle of paper chromatography. It is widely used in the detection of disease biomarkers, especially in line with the World Health Organization's REASSURED principle in clinical testing, that is, reasonable cost, high sensitivity, strong specificity, convenient operation, fast and stable, no need for special equipment, easy promotion, real-time feedback, easy sampling, and environmentally friendly. Cardiac markers refer to proteins or enzymes that are released into the peripheral blood and detected during the course of heart disease. They can reflect changes in the structure or function of the heart. Cardiac marker detection based on lateral flow chromatography technology uses the advantages of lateral flow chromatography technology to quickly, accurately and conveniently detect cardiac markers to meet the clinical needs for immediate detection of heart disease.
Market Drivers
Rising Prevalence of Cardiovascular Diseases:
The prevalence of cardiovascular diseases is increasing globally, especially in low- and middle-income countries. This has led to an increase in demand for cardiac marker testing, as cardiac marker testing plays an important role in early diagnosis, risk assessment, and treatment monitoring of heart disease.
Technological Advances and Cost Reductions:
With the advancement of science and technology, the sensitivity and specificity of lateral flow chromatography technology has continued to improve, while the cost of testing has gradually decreased. This has made cardiac marker testing based on lateral flow chromatography technology more popular and acceptable, further driving the development of the market.
Growing Demand for Home Testing:
Home testing (also known as self-testing) allows users to test self-collected samples and obtain results without the assistance of trained medical professionals. This testing method plays an important role in cardiovascular diseases and infectious diseases. With the improvement of consumers' health awareness and the popularity of home testing products, the demand for cardiac marker home testing products based on lateral flow chromatography technology is also increasing.
Support from policies and regulations:
The policy support of governments for medical health and technological innovation has provided a good policy environment for the development of the cardiac marker testing market based on lateral flow chromatography technology. For example, the government may introduce relevant policies to encourage innovation, reduce testing costs, and improve testing accuracy, thereby promoting the development of the market.
Population aging and increased medical needs:
As the global population ages, the elderly population's demand for medical and health services continues to increase. Heart disease is one of the common chronic diseases among the elderly, so the application prospects of cardiac marker detection based on lateral flow chromatography technology in the elderly population are broad.
In summary, the development of the cardiac marker detection market based on lateral flow chromatography technology is driven by a variety of factors, including the increase in the prevalence of cardiovascular diseases, technological advances and cost reductions, the growth of home testing needs, policy and regulatory support, and the aging population and increased medical needs. These factors have jointly promoted the rapid development and widespread application of the market.
This report aims to provide a comprehensive presentation of the global market for LFA-based Cardiac Marker, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of LFA-based Cardiac Marker by region & country, by Type, and by Application.
The LFA-based Cardiac Marker market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding LFA-based Cardiac Marker.
Market Segmentation
By Company
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
Segment by Type
Troponin
CK-MB
Myoglobin
Others
Segment by Application
Laboratory Testing
Point-of-care Testing
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of LFA-based Cardiac Marker company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of LFA-based Cardiac Marker in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of LFA-based Cardiac Marker in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index